Geranylgeranoic acid and the MAOB-CYP3A4 axis: a metabolic shift underlying age-related liver cancer risk
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Geranylgeranoic acid (GGA) levels decrease with age due to reduced monoamine oxidase B (MAOB) activity. Cytochrome P450 3A4 (CYP3A4) may compensate, offering insights into liver aging and cancer prevention.
Area Of Science
- Biochemistry
- Hepatology
- Gerontology
Background
- Geranylgeranoic acid (GGA), an acyclic isoprenoid, exhibits chemopreventive properties against hepatocellular carcinoma.
- Endogenous GGA synthesis in mammals primarily relies on geranylgeraniol oxidation by monoamine oxidase B (MAOB).
- Age-related decline in MAOB activity leads to reduced hepatic GGA levels, potentially impacting liver health.
Purpose Of The Study
- To review current findings on GGA biosynthesis and metabolism in the aging liver.
- To investigate the role of the MAOB-CYP3A4 axis in hepatic aging and GGA production.
- To explore the relevance of these metabolic pathways to age-related hepatic dysfunction and hepatocarcinogenesis.
Main Methods
- Literature review of studies on GGA metabolism and liver aging.
- Analysis of the MAOB-CYP3A4 enzymatic axis in GGA synthesis.
- Examination of age-dependent changes in hepatic metabolic pathways.
Main Results
- MAOB is the primary enzyme for endogenous GGA synthesis, but its activity diminishes with age.
- Cytochrome P450 3A4 (CYP3A4) emerges as a potential compensatory pathway for GGA production in MAOB-deficient conditions.
- The interplay between MAOB and CYP3A4 in GGA metabolism is crucial for understanding hepatic aging.
Conclusions
- The CYP3A4-GGA pathway offers a compensatory mechanism for age-related decline in MAOB activity.
- Understanding this enzymatic axis can elucidate the complexities of liver aging.
- Targeting the CYP3A4-GGA pathway may provide strategies for preventing age-related hepatocarcinogenesis, especially in older adults.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...